Chemotherapy Plus Trastuzumab in Treating Patients With Breast Cancer
Completed · Phase 1
Conditions studied: Breast Cancer
In brief
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of vinorelbine plus trastuzumab in treating patients who have refractory or metastatic breast cancer.
Key facts
- Study ID
- NCT00014430
- Run by
- Dartmouth-Hitchcock Medical Center
- People needed
- 13
- Starts
- 1999-11-01
- Last updated by the study team
- 2013-03-14
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Norris Cotton Cancer Center — Lebanon, New Hampshire, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.